STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROF
  4. [8-K] Profound Medical Corp. Reports Material Event

Profound Medical (NASDAQ: PROF) plans Q2 2026 financial results release and call

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Profound Medical Corp. plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by a conference call at 4:30 p.m. Eastern Time to review the results and discuss business developments. The call will be broadcast live and archived in the Investors section of the company’s website.

Profound Medical is a commercial-stage medical device company focused on interventional MRI (iMRI) procedures. Its flagship TULSA-PRO platform enables MRI-guided, incision-free prostate ablation, while its Sonalleve system provides non-surgical MRI-guided therapy for certain bone, tumor, and gynecologic conditions.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 results release date August 6, 2026 Date Profound Medical plans to release second quarter 2026 financial results
Conference call time 4:30 p.m. Eastern Time Scheduled start time for the August 6, 2026 conference call
Commission File Number 001-39032 Profound Medical’s Commission File Number under the Exchange Act
Investor relations phone 647.872.4849 Telephone number provided for investor relations contact Stephen Kilmer
interventional MRI (iMRI) medical
"a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures"
TULSA-PRO medical
"The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation"
TULSA Procedure medical
"Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time"
The Tulsa procedure is a minimally invasive medical treatment for an enlarged prostate that uses targeted pulses of sterile water vapor to destroy excess tissue and relieve urinary blockage. For investors, its clinical adoption, reimbursement status, and ease of use influence demand for the devices, shift patient flow away from long‑term drugs or major surgery, and can materially affect revenue and growth for device manufacturers, hospitals and urology clinics — like a new tool that changes how often and where a condition gets treated.
transurethral ultrasound ablation medical
"TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue"
Humanitarian Device Exemption (HDE) regulatory
"Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas"
adenomyosis medical
"as well as for common gynecologic conditions including uterine fibroids and adenomyosis"
Adenomyosis is a noncancerous condition where the lining of the uterus grows into the muscular wall, often causing heavy menstrual bleeding, pain, and sometimes difficulty becoming pregnant — think of wallpaper growing into the plaster beneath it. It matters to investors because its prevalence and symptoms drive demand for treatments, diagnostic tests and fertility services, influence clinical trial activity and regulatory decisions, and can shape market size and revenue potential for healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

When will Profound Medical (PROF) report its Q2 2026 financial results?
Profound Medical plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. A conference call to review the results and discuss business developments will follow at 4:30 p.m. Eastern Time.

What are the details of Profound Medical’s (PROF) Q2 2026 results conference call?
The Q2 2026 results conference call is scheduled for August 6, 2026 at 4:30 p.m. ET. Participants can register via the provided online registration link, and the call will be broadcast live and archived in the Investors section of the company’s website.

What does Profound Medical (PROF) specialize in?
Profound Medical is a commercial-stage medical device company specializing in interventional MRI (iMRI) procedures. Its technologies focus on incision-free, MRI-guided therapies that allow real-time visualization and targeted ablation for prostate disease, bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions.

What is TULSA-PRO from Profound Medical (PROF)?
TULSA-PRO is Profound Medical’s flagship MRI-guided platform for transurethral ultrasound ablation of prostate tissue. It enables the TULSA Procedure, allowing physicians to see, ablate, and confirm treatment in real time, supporting personalized prostate cancer care while aiming to reduce side effects like incontinence and erectile dysfunction.

What conditions does Profound Medical’s (PROF) Sonalleve system treat?
Sonalleve is an MRI-guided therapy system used for non-surgical treatment of pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, and for gynecologic conditions such as uterine fibroids and adenomyosis. It offers incision-free therapy, no blood loss during the procedure, and typically faster recovery.

What regulatory clearances do Profound Medical (PROF) technologies have?
TULSA-PRO is FDA-cleared in the United States for transurethral ultrasound ablation of prostate tissue and is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve has FDA HDE approval for osteoid osteomas in extremities and is cleared or approved in Europe, Canada, China, and Saudi Arabia.
False000162880800016288082026-07-162026-07-16iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 16, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada001-39032Not Applicable
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

 

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common SharesPROFThe Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

 

On July 16, 2026, Profound Medical Corp. (the “Company”) issued a press release announcing that it plans to release its second quarter financial results after market close on Thursday, August 6, 2026, and that the Company will host a conference call to review the financial results and discuss business developments at 4:30 p.m. Eastern Time on the same day. The press release contains additional information regarding how to access the conference call and webcast. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 Press Release, dated July 16, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PROFOUND MEDICAL CORP.
   
  
Date: July 16, 2026By: /s/ Rashed Dewan        
  Rashed Dewan
  Chief Financial Officer
  

 

EXHIBIT 99.1

Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Second Quarter 2026 Results Conference Call Details:

Date: Thursday, August 6, 2026

Time: 4:30 p.m. ET

Live Call Registration: https://register-conf.media-server.com/register/BI1680e67d2b6f4f81b268df3183400d7c

The call will also be broadcast live and archived on the Company's website in the Investors section here.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care — from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents